

## SenzaGen strengthens its market presence with expanded distribution channels

Lund, July 7, 2023

**SenzaGen has signed agreements with CRO companies GV Research Platform (GVRP) in India and Oroxcell in France for the distribution of the company's non-animal test portfolio, GARD® for chemical risk assessment. These strategic partnerships will enable the broadened distribution of GARD® to key markets driven by regulatory and industrial demand for alternative testing methods.**

India is a potentially important and large market where SenzaGen has already noticed increased interest in GARD® and has successfully secured orders from Indian customers. By collaborating with GVRP, a prominent CRO and distribution company in India, SenzaGen now gains access to a robust network and expertise in the country's thriving Life Science sector.

Similarly, SenzaGen's partnership with Oroxcell, an well-established CRO in France, strengthens the company's presence in one of its key geographic markets. France, known for its world-leading companies in cosmetics and pharmaceuticals, has long upheld a ban on animal testing for cosmetics as a member of the EU. With Oroxcell's strong focus on innovative, animal-free methods, SenzaGen will benefit from their broad network of contacts and specialist knowledge.

"Expanding SenzaGen's distribution channels is a crucial part of our scaling up as a commercial company. With the addition of two new quality distributors in important markets where we see an increasing demand for GARD®, we are taking important steps on our growth journey," says Peter Nählstedt, President and CEO of SenzaGen.

Both distributors will actively promote GARD® in their test portfolio, with a focus on biotech, pharma, chemical, and cosmetic companies seeking advanced testing solutions. All tests will be conducted at SenzaGen's GLP certified laboratory in Lund, Sweden.

### **About GV Research Platform (GVRP)**

Headquartered in Hyderabad, India, GV Research Platform (GVRP) is a pioneering Contract Research Organization focused on providing end-to-end solutions across the drug discovery continuum. Since its establishment in 2020, GVRP has made significant strides towards its vision of enabling efficient and affordable innovation through differentiated and customized R&D solutions. For more information, please visit [www.gvrp.in](http://www.gvrp.in)

### **About Oroxcell**

Oroxcell was founded in 2004. Specialized in efficacy, ADME and toxicity studies for pharmaceutical, cosmetics, nutrition and chemicals products, Oroxcell is a leading CRO company developing alternative methods to animal use. Once validated, these tests are provided as R&D services to its customers. For more information, please visit [www.oroxcell.com](http://www.oroxcell.com)



## Contacts

---

**Peter Nählstedt**, President and CEO, SenzaGen AB

Email: [peter.nahlstedt@senzagen.com](mailto:peter.nahlstedt@senzagen.com) | Mobile: +46 700 23 44 31

**Tina Dackemark Lawesson**, VP Marketing & Communications

Email: [tina.lawesson@senzagen.com](mailto:tina.lawesson@senzagen.com) | Mobile: +46 708 20 29 44

## About us

---

SenzaGen aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: [www.senzagen.com](http://www.senzagen.com).

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

## Attachments

---

[SenzaGen strengthens its market presence with expanded distribution channels](#)